Wire flash
China NMPA: To improve drug safety responsibility system and upgrade standards during 15th Five-Year Plan
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 20, Yang Sheng, Deputy Director of China's National Medical Products Administration (NMPA), announced at a State Council Information Office press conference that during the 15th Five-Year Plan period, the agency will issue opinions to improve the drug safety responsibility system. The NMPA plans to advance revisions to laws including the Medical Device Management Law and the Regulations on Protection of Traditional Chinese Medicine Varieties, fully implement the Drug Administration Law's Implementation Regulations, and refine supporting systems. A new action plan will upgrade standards for drugs and medical devices, and the 2030 edition of the Chinese Pharmacopoeia will be compiled with priority inclusion of essential medicines, medical insurance-covered drugs, and high-risk formulations. The NMPA will also strengthen research and development of standards in cutting-edge fields such as brain-computer interfaces, aiming to drive quality improvements through upgraded standards.
Source report
Jin10 Data, September 20 — Yang Sheng, Deputy Director of the National Medical Products Administration (NMPA), announced at a press conference hosted by the State Council Information Office on September 20 that during the 15th Five-Year Plan period, China will introduce a series of measures to strengthen drug safety and regulatory standards.
Key initiatives include:
- Issuing opinions to improve the drug safety responsibility system
- Advancing revisions to laws and regulations, including the Medical Device Management Law and the Regulations on Protection of Traditional Chinese Medicine Varieties
- Fully implementing the Implementation Regulations of the Drug Administration Law and refining supporting systems
- Launching an action plan to upgrade standards for drugs and medical devices
- Compiling the 2030 edition of the Chinese Pharmacopoeia, with priority inclusion of essential medicines, medical insurance-covered drugs, and high-risk formulations
- Strengthening research and development of standards in cutting-edge fields such as brain-computer interfaces
- Driving quality improvements through upgraded standards
(Source: Securities Times)
Source
金十数据Eastern
Part of this Story
China’s NMPA announces full-chain drug safety regulation upgrade for 15th Five-Year Plan